Skip to main content
. 2023 Mar 13;14:1359. doi: 10.1038/s41467-023-36976-1

Fig. 7. Study design.

Fig. 7

BCC basal cell carcinoma, DLBCL diffuse large B-cell lymphoma, ECOG PS Eastern Cooperative Oncology Group performance status, RP2D recommended phase II dose.